Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 8:12AM CST
MSI: 69.91 (-0.09), ATOS: 1.67 (+0.11), CGA: 2.02 (+0.09), DO: 35.21 (+0.36), RIOM: 3.04 (+0.06), FSC: 7.23 (+0.12), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), GALE: 1.68 (+0.06), NBG: 1.61 (+0.18)
Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
GlobeNewswire - Mon Feb 09, 6:18AM CST
-- Key PRESENT trial enrollment milestone achieved
GALE: 1.68 (+0.06)
Fantastic News: A Revolutionary New Breast Cancer Drug Is on the Way
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 8:12AM CST
Source: Komen Austin via Flickr . With the exception of skin cancer, breast cancer is the most commonly diagnosed type of cancer , making up one in every seven diagnoses in 2014 and nearly three in 10 cancer diagnoses for women. All told, that...
PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), GALE: 1.68 (+0.06), NVS: 102.20 (-0.17)
Galena Biopharma Announces Orexo's Filing of a Patent Infringement Lawsuit Against Actavis Concerning Abstral(R) (fentanyl) Sublingual Tablets in the U.S.
GlobeNewswire - Thu Feb 05, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that its partner, Orexo AB, has filed a patent infringement lawsuit in United States District Court for the District of New Jersey, against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis, Inc. and Actavis Pharma, Inc. (collectively "Actavis"
ACT: 285.37 (+3.71), GALE: 1.68 (+0.06)
In Case You Missed It, Breast Cancer Detection Just Took a Gigantic Leap Forward
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 8:12AM CST
Source: Flickr user Paul Falardeau. Cancer is a terrifying diagnosis in any form, but based on statistics from the World Health Organization, it's expected to see its diagnosis rate per year rise by nearly 60% over the next two decades. For...
PFE: 34.64 (-0.23), GALE: 1.68 (+0.06)
Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Jan 28, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 17 Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 10, 2015 at 11:00 a.m. ET at The Waldorf Astoria Hotel in New York, NY.
GALE: 1.68 (+0.06)
Advaxis: Heavily Promoted And Misleading Investors
Richard Pearson - Seeking Alpha - Wed Jan 21, 8:30AM CST
We are just a few weeks into the year, and already shares of Advaxis (NASDAQ: ADXS ) are up by more than 60%. But that's nothing. The shares have fully quadrupled since their November lows. Advaxis stock has suddenly become extremely liquid, trading...
ADXS: 7.18 (+0.06), KITE: 62.59 (+0.82), CYTR: 2.96 (+0.23), JUNO: 40.52 (+0.18), GALE: 1.68 (+0.06)
Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management
GlobeNewswire - Tue Jan 20, 6:08AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced it has hired Joseph Lasaga as Vice President, Business Development and Alliance Management, reporting to the President and CEO.
GALE: 1.68 (+0.06)
Galena Biopharma to Present at the Noble Financial Capital Markets 11th Annual Investor Conference
GlobeNewswire - Thu Jan 15, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Noble Financial Capital Markets 11 Annual Investor Conference. The presentation will take place on Tuesday, January 20, 2015 at 2:00 p.m. ET in Sandpiper Bay, Florida.
GALE: 1.68 (+0.06)